68 related articles for article (PubMed ID: 1355363)
21. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
Medinas RJ; Lambert DM; Tompkins WA
J Virol; 2002 Sep; 76(18):9079-86. PubMed ID: 12186891
[TBL] [Abstract][Full Text] [Related]
22. Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelope glycoprotein.
Harvima IT; Harvima RJ; Nilsson G; Ivanoff L; Schwartz LB
Biochem J; 1993 Jun; 292 ( Pt 3)(Pt 3):711-8. PubMed ID: 8318003
[TBL] [Abstract][Full Text] [Related]
23. Hemolysis of erythrocytes by granulysin-derived peptides but not by granulysin.
Li Q; Dong C; Deng A; Katsumata M; Nakadai A; Kawada T; Okada S; Clayberger C; Krensky AM
Antimicrob Agents Chemother; 2005 Jan; 49(1):388-97. PubMed ID: 15616319
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
25. A synthetic all D-amino acid peptide corresponding to the N-terminal sequence of HIV-1 gp41 recognizes the wild-type fusion peptide in the membrane and inhibits HIV-1 envelope glycoprotein-mediated cell fusion.
Pritsker M; Jones P; Blumenthal R; Shai Y
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7287-92. PubMed ID: 9636141
[TBL] [Abstract][Full Text] [Related]
26. Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein.
Wang JJ; Steel S; Wisniewolski R; Wang CY
Proc Natl Acad Sci U S A; 1986 Aug; 83(16):6159-63. PubMed ID: 2426711
[TBL] [Abstract][Full Text] [Related]
27. Lipid-binding and antimicrobial properties of synthetic peptides of bovine apolipoprotein A-II.
Motizuki M; Itoh T; Satoh T; Yokota S; Yamada M; Shimamura S; Samejima T; Tsurugi K
Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):215-21. PubMed ID: 10432319
[TBL] [Abstract][Full Text] [Related]
28. Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain.
Lanza P; Billetta R; Antonenko S; Zanetti M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11683-7. PubMed ID: 8265609
[TBL] [Abstract][Full Text] [Related]
29. Investigation of human immunodeficiency virus fusion peptides. Analysis of interrelations between their structure and function.
Slepushkin VA; Andreev SM; Sidorova MV; Melikyan GB; Grigoriev VB; Chumakov VM; Grinfeldt AE; Manukyan RA; Karamov EV
AIDS Res Hum Retroviruses; 1992 Jan; 8(1):9-18. PubMed ID: 1736943
[TBL] [Abstract][Full Text] [Related]
30. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
Barretina J; Blanco J; Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
Antivir Ther; 2003 Apr; 8(2):155-61. PubMed ID: 12741628
[TBL] [Abstract][Full Text] [Related]
31. A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41.
Jiang X; Jia Q; Lu L; Yu F; Zheng J; Shi W; Cai L; Jiang S; Liu K
Amino Acids; 2016 Dec; 48(12):2867-2873. PubMed ID: 27631437
[TBL] [Abstract][Full Text] [Related]
32. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
[TBL] [Abstract][Full Text] [Related]
33. Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.
Maerz AL; Drummer HE; Wilson KA; Poumbourios P
J Virol; 2001 Jul; 75(14):6635-44. PubMed ID: 11413331
[TBL] [Abstract][Full Text] [Related]
34. Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues.
Delahunty MD; Rhee I; Freed EO; Bonifacino JS
Virology; 1996 Apr; 218(1):94-102. PubMed ID: 8615045
[TBL] [Abstract][Full Text] [Related]
35. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
36. Monkey pepsinogens and pepsins. IV. The amino acid sequence of the activation peptide segment of Japanese monkey pepsinogen.
Kageyama T; Takahashi K
J Biochem; 1980 Jul; 88(1):9-16. PubMed ID: 6773933
[TBL] [Abstract][Full Text] [Related]
37. Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope.
Sabatier JM; Mabrouk K; Moulard M; Rochat H; Van Rietschoten J; Fenouillet E
Virology; 1996 Sep; 223(2):406-8. PubMed ID: 8806580
[TBL] [Abstract][Full Text] [Related]
38. Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.
Haynes BF; Arthur LO; Frost P; Matthews TJ; Langlois AJ; Palker TJ; Hart MK; Scearce RM; Jones DM; McDanal C
J Exp Med; 1993 Mar; 177(3):717-27. PubMed ID: 7679708
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
[TBL] [Abstract][Full Text] [Related]
40. The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.
Huang JH; Yang HW; Liu S; Li J; Jiang S; Chen YH
Biochem J; 2007 May; 403(3):565-71. PubMed ID: 17223796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
